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Abstract: Aims: Darbepoetin-α (DPO), a long-acting erythropoietin analog, has been shown to protect the liver 
against cholestatic injury, to exert an antifibrotic effect, and to increase the survival time in a model of common bile 
duct ligation. Here we evaluate whether these tissue-protective effects are caused by DPO induced regulation of 
hepatobiliary transporters. Main methods: C57BL/6J mice underwent common bile duct ligation and were treated 
with either DPO or physiological saline. Time dependent (2, 5, 14, 28 days after bile duct ligation) protein expression 
of different hepatobiliary transporters which have been established to play an important role in hepatocellular (i) 
bile acid uptake, (ii) bile acid excretion, and (iii) retrograde bile acid efflux were assessed. mRNA and protein expres-
sion of Lhx2, an important negative regulator of hepatic stellate cell activation, was determined. Key findings: Saline 
treated cholestatic mice impress with increased mRNA expression of Lhx2 as a defense mechanism, while there 
is less need for such an upregulation in mice treated with DPO. Whereas Ntcp (slc10a1) protein expression is sup-
pressed as early as 2 days after bile duct ligation to 40% in untreated animals, DPO treated mice exhibit decreased 
protein level not before day 5. Similarly, the steady decline of Mrp4 (abcc4) protein level during extrahepatic cho-
lestasis in control treated animals does not occur upon DPO application. Significance: The collected data show that 
DPO affects expression of hepatobilliary transporters during obstructive cholestasis but do not provide sufficient 
evidence to demonstrate a direct correlation between this regulation and hepatoprotection by DPO.
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Introduction
Intrahepatic accumulation of bile acids causes 
proinflammation, oxidative stress, mitochon-
drial damage and severe hepatocellular injury, 
ultimately leading to liver fibrosis and cirrhosis 
[1, 2]. Functional characterization, cloning, and 
localization of hepatobiliary transporter pro-
teins provided a molecular understanding of 
the mechanisms underlying bile flow and the 
retention of toxic bile acids in cholestatic disor-
ders [3]. Hepatic uptake and efflux transport-
ers, located on either sinusoidal or canalicular 
membrane, contribute to the vectorial trans-
port of biliary constituents, such as bile acids, 
bilirubin glucuronides, and a variety of xenobi-
otics from sinusoidal blood into bile [4].
Regulation of hepatobiliary transporter sys-
tems in cholestasis may be regarded as a pro-
tective feedback mechanism of the hepato-
cytes to minimize the hepatic uptake or to 
enhance the hepatic efflux of bile acids [5]. On 
the other hand, regulation of hepatobiliary 
transporters is possibly only a secondary event 
which is insufficient to prevent the hepatocellu-
lar accumulation of toxic compounds.
Pharmacological therapy for cholestatic disor-
ders is limited. Although used in an empirical 
manner, ursodeoxycholic acid is the only dis-
ease-modifying drug therapy with evidence of 
efficacy. However, a majority of patients are 
incomplete responders to ursodeoxycholic acid 
[6]. Increasing information on the molecular 
mechanisms of bile acid transport has added 
new information to the usage of empiric treat-
ment strategies and extended their application 
[7].
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We have recently shown that Darbepoetin-α 
(DPO), a long-acting erythropoietin analog, pro-
tects the liver against cholestatic injury, exerts 
an antifibrotic effect, and increases the survival 
time in a model of common bile duct ligation 
(BDL) [8]. In the present study, we determined 
the time dependent expression profiles of dif-
ferent hepatobiliary transporters (see Figure 1) 
during obstructive cholestasis and examined 
whether changes in expression are associated 
with hepatoprotection shown by DPO.
Materials and methods
Animal model
Male C57BL/6J mice were purchased from 
Charles River Laboratories (Sulzfeld, Germany) 
and were used at 8 - 10 weeks of age with a 
body weight of 23 - 26 g. Animals were kept on 
water and standard laboratory chow ad libitum. 
The experiments were conducted in accor-
dance with EU Directive 2010/63/EU for ani-
mal experiments and the German legislation on 
protection of animals. Mice were anesthetized 
with isoflurane and BDL was performed after 
midline laparotomy. The common bile duct was 
ligated 3 times with 5-0 silk and transected 
between the 2 distal ligations. Sham operation 
was performed similarly except for ligation and 
transection of the bile duct (n = 6). A total of 
eighty BDL mice were randomized into two 
groups. Darbepoetin-α (10 μg/kg body weight, 
Aranesp; Amgen Europe, Breda, The 
Netherlands) or the same volume of isotonic 
saline was injected intraperitoneally in a blind-
ed fashion every third day beginning at the first 
day after BDL. To obtain blood and liver sam-
ples, mice (10 animals per group at each time 
point) were sacrificed at days 2, 5, 14, and 28 
after BDL.
Hematological measurements and histopathol-
ogy
Animals were anesthetized and exsanguinated 
by puncture of the vena cava inferior. Plasma 
concentration of total bilirubin served as 
parameter of cholestasis. Liver tissue samples 
were fixed in formalin for 2 - 3 days and embed-
ded in paraffin. Five-micrometer sections were 
stained with Hematoxylin and Eosin (H&E) for 
routine examination and quantification of bile 
infarcts. All samples from a series of experi-
ments were stained simultaneously and evalu-
ated in a blinded fashion. For histomorphomet-
ric analysis images of twenty random low-power 
fields (10× magnification, Olympus BX 51, 
Hamburg, Germany) were acquired with a Color 
View II FW camera (Color View, Munich, 
Germany) and evaluated by means of an image 
analysis system (Adobe Photoshop, Adobe 
Systems, Uxbridge, UK). Bile infarcts were 
quantified in H&E stained sections in a similar 
fashion and the percentage of the focal necro-
sis surface to the total liver section area was 
assessed.
Real-time PCR
Total RNA from liver tissue was isolated using a 
RNeasy Mini Kit (Qiagen, Germany) according 
to the manufacturer’s instructions. Total RNA 
were eluted in 30 µl of nuclease-free water, 
quantified spectrophotometrically at 260 nm, 
and kept at -80°C until use. First strand cDNA 
was synthesized by reverse transcription of 
2 µg of total RNA using oligo(dT)18 primer 
(Biolabs, Frankfurt am Main, Germany) and 
Superscript II RNaseH-Reverse Transcriptase 
(Invitrogen, Karlsruhe, Germany) in the 
presence of dNTP’s, 5 x first strand buffer and 
dithiothreitol at 72°C for 10 min and 42°C for 
60 min. The reverse transcriptase was 
inactivated by 95°C for 5 min. Expression levels 
of murine collagen-(I)-α1 and Lhx2 mRNA were 
quantified relative to control samples 
(LightCycler System 1.5 Roche, Mannheim, 
Germany) and normalized to the expression of 
the housekeeping gene GAPDH. For our 
approach we used SYBR Green I (Roche, 
Manheim, Germany) for the detection of dsDNA 
Figure 1. Localization of hepatocellular transporters 
on basolateral and canalicular hepatocyte mem-
brane.
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amplified in the PCR. Primers (Lhx2 forward: 
5́ -GTCCAGGACCCGGGGCAGAT-3 ,́ reverse: 5́ - 
CGAGGCGTTGGACAGCTCCG-3 ;́ collagen-(I)-α1 
forward: 5́ -GAAACCCGAGGTATGCTTGA-3 ,́ rev-
erse: 5-GACCAGGAGGACCAGGAAGT-3´) were 
designed spanning introns to eliminate false 
positive signals from contaminating genomic 
DNA as well as to anneal at about 55°C to 
combine both reactions of GAPDH and target 
gene in the same run. The real-time PCR 
program included a 10 min denaturation step 
followed by 40 - 50 amplification cycles. After 
each LightCycler run, a melting curve analysis 
was performed to analyze the PCR products. 
LightCycler PCR products were separated by 
1% agarose (peqGOLD Universal Agarose; 
peQLab Biotechnologie, Erlangen, Germany) 
gel electrophoresis containing 0.5 µg/ml 
ethidium bromide to confirm the right 
amplification products. For the quantification of 
gene expression, duplicates were run in the 
LightCycler for both genes. The reaction without 
cDNA template was also performed as a 
negative control. Specificity of the amplification 
was verified by melt-curve analysis and 
evaluation of efficiency of PCR amplification.
Immunoblot analysis
For Western blot analysis of protein levels of 
Lhx2, Ntcp (scl10a1), Oatp2b1 (slco2b1), Mrp2 
(abcc2), Bsep (abcb11), Mrp4 (abcc4), Mrp5 
(abcc5), and ß-actin liver tissue was homoge-
nized in lysis buffer (10 mM Tris pH 7.5, 10 mM 
NaCl, 0.1 mM EDTA, 0.5% Triton-X 100, 0.02% 
NaN3, and 0.2 mM PMSF, protease inhibitor 
cocktail), incubated for 30 min on ice and cen-
trifuged for 15 min at 10,000 x g. Protein con-
tent were assayed by bicinchoninic acid (BCA) 
method (Pierce, Biotechnology) with bovine 
serum albumin (BSA) (Pierce, Biotechnology) as 
standard. Per lane 20 µg was separated on a 
8% (abcc2, abcb11, abcc4, and abcc5), 10% 
(slco2b1) or 12% (Lhx2, slc10a1) SDS gel and 
transferred to a polyvinyldifluoride membrane 
(Immobilon-P; Millipore, Eschborn, Germany). 
After blockade with 2% BSA (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA), mem-
branes were incubated over night at 4°C with a 
goat polyclonal anti-Lhx2-antibody (1:1,000; 
Santa Cruz Biotechnology), a rabbit polyclonal 
anti-scl10a1-antibody (1:1,000; abcam, 
Cambridge, UK), a rabbit polyclonal anti-
slco2b1-antibody (1:1,000; abcam), a goat 
polyclonal anti-abcc2-antibody (1:400; Santa 
Cruz Biotechnology), a rabbit polyclonal anti-
abcb11-antibody (1:200; abcam), a goat poly-
clonal anti-abcc4-antibody (1:500; abcam), 
and a goat polyclonal anti-abcc5-antibody 
(1:250; Santa Cruz Biotechnology) followed by 
a secondary peroxidase-linked goat anti-rabbit 
antibody (slc10a1, slco2b1, abcb11; 1:10,000; 
Cell Signaling Technology) or by a secondary 
peroxidase-linked donkey anti-goat antibody 
(Lhx2, abcc4; 1:10,000; abcc2; 1:25,000; 
abcc5; 1:15,000, Santa Cruz Biotechnology).
Protein expression was visualized by means of 
luminol-enhanced chemiluminescence (ECL 
plus; Amersham Pharmacia Biotech, Freiburg, 
Germany) and digitalized with ChemiDoc™ XRS 
System (Bio-Rad Laboratories, Munich, 
Germany). Signals were densitometrically 
assessed (Quantity One; Bio-Rad Laboratories) 
and normalized to the β-actin signals (mouse 
monoclonal anti-β-actin antibody; 1:20,000; 
Sigma).
Statistics
Data are presented as mean ± s.e. To compare 
BDL groups with sham operated animals for 
Table 1. Bilirubin concentration, bile infarcts, and mRNA expression of collagen-(I)-α1 after BDL
sham
2 days after BDL 5 days after BDL 14 days after BDL 28 days after BDL
con DPO con DPO con DPO con DPO
bilirubin (mmol/l) 11 ± 0 247 ± 33 161 ± 17# 343 ± 26 331 ± 30 651 ± 42 554 ± 58 371 ± 44 302 ± 41





















Plasma bilirubin concentration, histologically assessed bile infarcts and hepatic mRNA expression of collagen-(I)-α1 in sham 
operated mice (n = 3 – 4) and in animals at 2, 5, 14, and 28 days after BDL with administration of either 10 µg/kg body weight 
darbepoetin-α (DPO) or physiological saline (con) every third day, beginning 24 h after surgery (n = 6 - 10 per group and time 
point). Data are given as mean ± s.e. #p < 0.05 versus control at the respective time point. Data are adopted from (Sigal et al. 
2010).
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Figure 2. mRNA and protein expression of Lhx2. mRNA expression of Lhx2 (A) and protein expression of Lhx2 
(B) in liver tissue of sham operated animals (n = 3 - 4) and of animals at 2, 5, 14, and 24 days after BDL with 
administration of either 10 µg/kg body weight darbepoetin-α (D) or physiological saline (C) every third day, beginning 
24 h after surgery (n = 3 - 5 per group and time point). The expression levels were normalized to GAPDH or ß-actin, 
respectively. Data are given as mean ± s.e. *p < 0.05 versus sham (S); #p < 0.05 versus control (C) at the respective 
time point.
significant differences One Way Analysis of 
Variance for normally distributed populations or 
Kruskal-Wallis Analysis of Variance on Ranks 
for non-normal populations was performed. To 
determine significant differences between 
means of saline and DPO treated animals at 
the same time point unpaired t-test for normally 
distributed populations was performed. 
Shapiro-Wilk test was used to test for a normal-
ly distributed population. Data were considered 
significant when p < 0.05. Statistical analysis 
was performed using the Sigma Plot software 
package (Version 12.0, Systat Software Inc, 
San Jose, CA, USA).
Results
Time profiles of bilirubin concentration and 
bile infarcts after BDL
Impaired bile excretion resulted in elevated 
total bilirubin concentration in plasma of BDL 
mice reaching a maximum at 14 days. 
Administration of DPO significantly reduced bili-
rubin levels at day 2, when compared to saline 
treated controls (Table 1). The retention of bile 
salts elicited a toxic response and led to cellu-
lar damage of hepatocytes as revealed by histo-
morphometric analysis of biliary infarcts in liver 
tissue. These clusters of injured hepatocytes 
could be significantly diminished by DPO treat-
ment at both day 2 and 14 post BDL (Table 1).
Time profiles of hepatic stellate cell activation 
and collagen deposition after BDL
The major source of extracellular matrix pro-
teins in liver fibrosis are activated hepatic stel-
late cells (HSCs) [9, 10]. The LIM homeobox 
gene Lhx2 is an important negative regulator of 
HSC activation and fibrogenesis. Lhx2-/- embry-
os contain numerous activated HSCs and dis-
play a progressively increased deposition of 
extracellular matrix proteins associated with 
liver fibrosis. Overexpression of Lhx2 in cul-
tured stellate cells leads to decreased cell acti-
vation [9, 10]. In the present study, Lhx2 mRNA 
was highly up-regulated in cholestatic mice 
without DPO therapy at day 2 (Figure 2A). Lhx2 
protein level was slightly increased in DPO 
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treated animals at day 2, whereas sham treat-
ed mice showed significantly elevated level of 
Lhx2 at day 5 after BDL (Figure 2B). Activation 
of stellate cells led to marked increase of 
collagen-(I)-1α mRNA expression, which was 
significantly reduced by DPO application at 
both day 2 and 14 after BDL (Table 1).
Expression time profiles of hepatic transport-
ers after BDL
Expression of various hepatic transport pro-
teins during extrahepatic cholestasis (see 
Figure 1) was examined by Western Blot analy-
sis. The vectorial transport of bile acids in 
hepatocytes includes carrier-mediated uptake 
at the basolateral membrane, translocation 
through the cell, and active transport across 
the canalicular plasma membrane into bile or 
efflux via the basolateral membrane back into 
sinusoidal blood [3, 5].
Bile acid uptake across the basolateral mem-
brane
Quantitatively relevant uptake transporters in 
the basolateral membrane include the sodium 
taurocholate contransporting polypeptide 
(NTCP/Ntcp) and the organic anion transporting 
polypeptides (OATPs/Oatps) [3]. Compared with 
sham-operated animals, the relative protein 
expression of Ntcp declined by 60% at 2 days 
after BDL in untreated animals, while the 
expression was slightly increased after treat-
ment with DPO. Ntcp level further decreased to 
30% at 28 days after ligation in both saline and 
DPO treated mice (Figure 3A). Extrahepatic 
cholestasis downregulated liver Oatp2b1 
expression at 2 days to about 50% compared 
to sham operated mice. This downregulation 
remained unaffected by DPO treatment (Figure 
3B).
Bile acid excretion across the canalicular 
membrane
Both, multidrug resistance protein 2 (MRP2/
Mrp2) and bile salt exporting pump (BSEP/
Bsep) are major contributors to bile acid inde-
pendent and bile acid dependent bile flow via 
the canalicular membrane into bile [3]. In the 
liver, Mrp2 protein expression time-dependent-
ly decreased in all cholestatic groups to finally 
Figure 3. Protein expression of basolateral membrane transporters. Protein expressions of Ntcp (A) and Oatp2b1 (B) 
in liver tissue of sham operated animals (n = 3) and of animals at 2, 5, 14, and 24 days after BDL with administration 
of either 10 µg/kg body weight darbepoetin-α (D) or physiological saline (C) every third day, beginning 24 h after 
surgery (n = 6 per group and time point). The expression levels were normalized to ß-actin. Data are given as mean 
± s.e.
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50% at 28 days after BDL. This decline 
remained unaffected by DPO treatment (Figure 
4A). Expression of Bsep showed unique chang-
es; it decreased by 60% until 14 days after BDL 
in saline treated animals, and thereafter 
increased 2.3-fold at 28 days of extrahepatic 
cholestasis (Figure 4B). Quite similar results 
were observed in DPO treated animals, howev-
er, the Bsep protein level already started to 
increase at 14 days after BDL (Figure 4B).
Retrograde bile acid efflux across the basolat-
eral membrane
MRP4/Mrp4 and Mrp5/Mrp5 are unidirectional 
pumps releasing organic anions into the sinu-
soidal blood, particularly when the activity of 
canalicular efflux pumps is impaired [3, 7, 11]. 
Recent research suggests that Mrp4 rather 
than Mrp3 represents the major hepatic baso-
lateral bile acid export pump in obstructive cho-
lestasis in mice [12, 13]. However, liver Mrp4 
protein expression was unchanged at 2 and 5 
days after BDL in saline treated animals, while 
a decrease to 35% at 14 days and thereafter an 
increase to 120% at 28 days were observed. In 
contrast DPO treated mice revealed nearly 
unchanged Mrp4 protein expression until day 
14 after BDL (Figure 5A). The role of Mrp5 in 
bile acid transport is currently under investiga-
tion and it is speculated that Mrp5 could pos-
sibly contribute to the alternative bile acid elim-
ination in cholestasis [11, 14]. Obstructive 
cholestasis decreased Mrp5 protein expres-
sion in mouse liver to about 40% at all time-
points studied. There were no differences 
between treatment groups (Figure 5B).
Discussion
Bile acid induced liver injury as a consequence 
of extrahepatic cholestasis may progress to 
fibrosis and cirrhosis, ultimately leading to 
death unless the obstructive lesion is removed 
or the bile duct is bypassed. There is accumu-
lating evidence that several hepatic transport-
ers undergo adaptive regulation in response to 
cholestatic liver injury [3, 7]. These adaptions 
Figure 4. Protein expression of canalicular membrane transporters. Protein expressions of Mrp2 (A) and Bsep (B) in 
liver tissue of sham operated animals (n = 3) and of animals at 2, 5, 14, and 24 days after BDL with administration 
of either 10 µg/kg body weight darbepoetin-α (D) or physiological saline (C) every third day, beginning 24 h after 
surgery (n = 6 per group and time point). The expression levels were normalized to ß-actin. Data are given as mean 
± s.e.
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are presumed to minimize the hepatic retention 
of bile acids and other potentially toxic sub-
strates. However, it is quite possible that this 
response only reflects a non-effective conse-
quence to the accumulation of toxic bile consti-
tutes in hepatocytes. In the present study, we 
characterized the time-dependent effect of 
extrahepatic cholestasis on the expression of 
different hepatobiliary transport proteins which 
have been established to play an important 
role in (i) bile acid uptake across the basolater-
al membrane, (ii) bile acid excretion across the 
canalicular membrane, and (iii) retrograde bile 
acid efflux across the basolateral membrane 
(see Figure 1).
The protein level of the predominant basolater-
al uptake transporter Ntcp has been shown to 
be downregulated in obstructive cholestasis 
model of common BDL up to 7 days [5, 13, 15]. 
The present study confirms the downregulation 
of Ntcp protein as early as 2 days after BDL and 
extends our knowledge indicating that the 
expression remains decreased up to 28 days. 
The sodium independent transport is mediated 
by the OATPs/Oatps which belong to the solute 
carrier organic transporter family. The OATPs 
were thought to be secondary active transport-
ers and the main human OATPs (1A2, 1B1, 
1B3, and 2B1) are expressed at the basolateral 
membrane of the hepatocyte and primarily 
transport unconjugated bile salts [16]. It has 
been shown that protein expression of mem-
bers of the Oatp1 family (1a4, 1b2) is unchanged 
[17] or slightly reduced [18] during obstructive 
cholestasis in rats. First characterized with 
rather limited substrate specificity compared to 
other OATPs [19], in more recent studies the 
substrate specificity of OATP2B1 has been 
broadened, indicating that OATP2B1 might be 
involved in elimination of numerous endo- and 
xenobiotics [20]. Here we demonstrate a slight 
reduction of Oatp2b1 protein expression as 
early as 2 days after BDL.
In liver, MRP2/Mrp2 serves as the canalicular 
efflux pump for many organic anions, particu-
larly for bilirubin glucuronosides. The absence 
Figure 5. Protein expression of efflux basolateral membrane transporters. Protein expressions of Mrp4 (A) and 
Mrp5 (B) in liver tissue of sham operated animals (n = 3) and of animals at 2, 5, 14, and 24 days after BDL with 
administration of either 10 µg/kg body weight darbepoetin-α (D) or physiological saline (C) every third day, beginning 
24 h after surgery (n = 6 per group and time point). The expression levels were normalized to ß-actin. Data are given 
as mean ± s.e. *p < 0.05 versus sham (S); #p < 0.05 versus control (C) at the respective time points.
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of functional Mrp2 from the canalicular mem-
brane causes conjugated hyperbilirubinemia 
[21]. However, loss of Mrp2 function is usually 
well tolerated by compensatory upregulation of 
other membrane transporters [21]. Mrp2 pro-
tein expression was considerably decreased in 
obstructive cholestasis in rats during different 
time periods [18, 22-25]. For mice, results are 
conflicting. The group of Mennone reported 
both no change in protein expression at 7 days 
after BDL in mice maintained in an equivalent 
129/Sv and C57BL6 mixed background [13] as 
well as downregulation of Mrp2 protein expres-
sion by 50% at the same time point in FVB/129 
mice [26]. Wagner et al. showed that Mrp2 pro-
tein level remained preserved at 1, 3, and 7 
days after common BDL in C57BL6 mice [27]. 
Herein, we observed a time-dependent decline 
from 70% at 2 days to 50% at 28 days after 
BDL in C57BL6 mice. The second main cana-
licular export pump Bsep is primarily expressed 
in the liver and mice deficient for Bsep develop 
intrahepatic cholestasis [16]. Mutations in 
human BSEP lead to the inherited cholestatic 
disorder progressive familial intrahepatic cho-
lestasis type 2 [4]. BSEP has been most recent-
ly suggested as a potential therapeutic target 
in cholestatic disorders [28]. However, in con-
trast to humans, mice lacking the Bsep gene 
exhibit only mild, non-progressive, but persis-
tent intrahepatic cholestasis [4]. Our findings 
are consistent with previous studies in mice in 
which Bsep protein level remained unchanged 
up to 7 days after BDL [26, 27, 29]. Moreover, 
we show that Bsep protein expression reduces 
to about 40% at 2 weeks and doubles thereaf-
ter at 4 weeks post BDL.
It is speculated that Mrp4 represents the major 
hepatic basolateral bile acid transporter in ani-
mal models of obstructive cholestasis [12, 13]. 
Induction of hepatic Mrp4 expression is consid-
ered to be an adaptive response counteracting 
intracellular bile acid toxicity by increased efflux 
of bile acids [12]. Herein, we observed a tran-
sient decline of Mrp4 protein level and only 
minor induction at 4 weeks after BDL. The role 
of Mrp5 in bile acid transport remains elusive 
but possible because it is localized in basolat-
eral membranes and expressed in the liver 
[14]. An increase of MRP5 protein was detected 
in livers of patients with primary biliary cirrhosis 
[11]. Surprisingly, we observed a decline of 
Mrp5 protein level after obstructive 
cholestasis.
Delayed necro-inflammation and macrophage 
infiltration upon DPO application suppressed 
the activation of HSCs, resulting in attenuation 
of fibrogenesis [8]. Whereas mRNA expression 
of Lhx2, a negative regulator of HSC activation, 
is rapidly upregulated as a defense mechanism 
in cholestatic mice, there is less need for this 
upregulation in mice treated with DPO. The lim-
ited increase of Lhx2 mRNA in DPO treated cho-
lestatic mice seems to be a consequence of 
the anti-inflammatory effects mediated by DPO.
The collected data do not provide sufficient evi-
dence to demonstrate a direct correlation 
between hepatoprotection by DPO and chang-
es in hepatobiliary transporter expression dur-
ing obstructive cholestasis. However, DPO 
treatment of bile duct ligated mice results in a 
preservation of basic protein levels of two 
transporter systems. Whereas Ntcp protein 
expression is suppressed as early as 2 days 
after BDL to 40% in untreated animals, DPO 
treated mice exhibit decreased protein level 
not before day 5. Similarly, the steady decline 
of Mrp4 protein level during extrahepatic cho-
lestasis in control treated animals does not 
occur upon DPO application. Bile acid accumu-
lation during obstructive cholestasis results in 
a systemic release of pro-inflammatory cyto-
kines, such as tumor necrosis factor-alpha 
(TNF-α), interleukin-1beta (IL-1β), and interleu-
kin-6 (IL-6), which is accompanied by activation 
of NF-kappaB [30, 31]. Pro-inflammatory cyto-
kines are potent inhibitors of transporter 
expression [7]. In livers of patients with inflam-
mation-induced cholestasis, expressions of 
NTCP, OATP2, and BSEP were reduced [32]. 
IL-1β treatment of hepatocytes markedly 
reduced Ntcp RNA level and Ntcp promoter 
activity [33], whereas reduced IL-1β and TNF-α 
upon Kupffer cell depletion blocks cytokine-
mediated Ntcp suppression in sepsis-associat-
ed cholestasis [34]. Erythropoietin (EPO) acts 
as a potent anti-inflammatory immune modula-
tor by specifically targeting NF-kB p65-driven 
inflammatory effector pathways [35] and thus 
impairs formation of pro-inflammatory cyto-
kines [36-38]. We have already shown that DPO 
treatment of bile duct ligated mice markedly 
reduced the infiltration of macrophages into 
the liver and inhibited the perpetuation of the 
necro-inflammatory reaction [8]. Concluding, 
the herein observed delayed suppression of 
Ntcp and Mrp4 protein levels in DPO treated 
animals, particularly at the early stage of cho-
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lestasis, is rather a result of this reduced necro-
inflammation than a direct action of DPO.
Several signal transduction events have been 
implicated in the tissue protective effects of 
EPO and its analogues including induction of 
JAK2 (Janus kinase-2) and STAT-5 (signal trans-
ducer and activator of transcription-5) depen-
dent signaling cascades as well as activation of 
JNK (c-Jun N-terminal kinase) and MAPK (mito-
gen-activated protein kinase) pathways [37]. 
We and others have previously demonstrated 
that EPO analogues attenuate liver injury in a 
model of fulminant hepatic failure. The protec-
tion is mediated by decreased activation of the 
JNK pathway and thus reduced activities of 
TNF-α and IL-1ß [36, 38]. Reduced Ntcp gene 
expression in cholestatic liver injury has been 
attributed to JNK-dependent suppression of 
key Ntcp promoter activators, primarily HNF1 
(hepatocyte nuclear factor 1) and RXR:RAR 
(nuclear receptor heterodimer retinoid X 
receptor:retinoic acid receptor) [33]. Thus, the 
inhibited suppression of Ntcp expression in bile 
duct ligated animals treated with DPO might 
conceivably be caused via DPO dependent 
reduction of JNK activity. However, suppressed 
JNK activity could as well be mediated through 
anti-inflammatory effects of DPO, because JNK 
pathway has been shown to be activated by 
pro-inflammatory cytokines [39].
In conclusion, on the basis of the data present-
ed a cause-and-effect relationship between 
changes in hepatobiliary transporter expres-
sion and hepatoprotection by DPO could not be 
established. It is quite possible that the 
observed changes are a secondary effect of 
anti-inflammatory action of DPO. Increasing 
information on the cause-and-effect relation-
ship of possible treatment strategies will repre-
sent a major step towards the development of 
novel, more effective therapeutic strategies.
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